NCT04505436: An ongoing trial by Hanmi Pharmaceutical Company Limited
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04505436 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 31, 2020 |
| Completion date | June 27, 2026 |
| Required reporting date | June 27, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |